Contemporary Approaches to Immunotherapy of Solid Tumors

Alla V. Kuznetsova,Xenia A. Glukhova,Olga P. Popova,Igor P. Beletsky,Alexey A. Ivanov

DOI: https://doi.org/10.3390/cancers16122270

2024-06-20

Cancers

Abstract:In recent years, the arrival of the immunotherapy industry has introduced the possibility of providing transformative, durable, and potentially curative outcomes for various forms of malignancies. However, further research has shown that there are a number of issues that significantly reduce the effectiveness of immunotherapy, especially in solid tumors. First of all, these problems are related to the protective mechanisms of the tumor and its microenvironment. Currently, major efforts are focused on overcoming protective mechanisms by using different adoptive cell therapy variants and modifications of genetically engineered constructs. In addition, a complex workforce is required to develop and implement these treatments. To overcome these significant challenges, innovative strategies and approaches are necessary to engineer more powerful variations of immunotherapy with improved antitumor activity and decreased toxicity. In this review, we discuss recent innovations in immunotherapy aimed at improving clinical efficacy in solid tumors, as well as strategies to overcome the limitations of various immunotherapies.

oncology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the key challenges in immunotherapy for solid tumors, especially how to improve clinical efficacy and overcome the limitations of existing immunotherapy methods. Specifically:

1. **Protective mechanisms in the tumor microenvironment (TME)**: The paper discusses the protective mechanisms existing in solid tumors and their microenvironments, which enable tumors to evade the attack of the immune system. For example, components such as tumor - associated fibroblasts (CAFs) and extracellular matrix (ECM) form an immunosuppressive network, hindering the infiltration and function of immune cells.

2. **Dysfunction of immune cells**: The paper points out that immune cells in the tumor microenvironment, such as T cells, natural killer cells (NK cells) and dendritic cells (DCs), will experience dysfunction or "exhaustion" under continuous antigen exposure, expressing multiple inhibitory receptors (immune checkpoints), thereby inhibiting their ability to proliferate and produce pro - inflammatory cytokines.

3. **Heterogeneity of solid tumors**: Different types of solid tumors have different molecular subtypes and immunophenotypes, which lead to differences in treatment responses. The paper emphasizes the importance of classifying tumors by gene expression profiling and immunohistochemistry techniques to better predict treatment effects and select appropriate treatment strategies.

4. **Limitations of immunotherapy**: Although many immunotherapy methods have been clinically approved, each method has inherent limitations, such as insufficient targeting specificity, drug resistance, immunosuppression, etc. The paper explores how to improve the efficacy of immunotherapy through innovative strategies, reduce toxic and side effects, and improve the treatment effects on different types of solid tumors.

In summary, this paper aims to comprehensively analyze the current progress and challenges in immunotherapy for solid tumors and propose improvement strategies in order to achieve more effective clinical efficacy.